PMDA to Specify Target Overall Review Period for Regenerative Medicine Products: FY2019-2023 Plan

January 17, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) on January 16 presented a draft of its fourth midterm plan for FY2019-2023, newly setting the target total review time for regenerative medicine products. The agency aims to achieve a total review time...read more